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MinireviewP53 and Prognosis:
New Insights and Further Complexity
therefore usually kept under very tight control, in large
part by the rapid turnover of the p53 protein, which is
expressed in normal tissues at extremely low levels. A
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identified, including Mdm2 (or Hdm2), Pirh2, and Cop12Department of Biological Sciences
(Corcoran et al., 2004). While the exact role of someColumbia University
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regulation of p53 stability is as yet unclear, numerous
studies have shown that Mdm2 plays a pivotal role in
restraining p53. So while loss of Mdm2 leads to an acti-
Despite the massive amount of knowledge that has vation of p53 that is lethal during embryogenesis, the
accumulated about p53, there is still much to learn pathways that allow stress-induced inhibition of Mdm2
about its role in tumor suppression. New papers now are essential to activate p53s tumor suppressive activ-
provide evidence that levels of Mdm2 in humans or ity (Iwakuma and Lozano, 2003). Indeed, failures in the
presence of mutant forms of p53 in mice can have systems that allow Mdm2 to be switched off have been
profound impacts on survival and tumorigenesis. convincingly linked to cancer development, presumably
These findings may lead to new diagnostic and thera- because they result in an inability to properly stabilize and
peutic approaches to treating cancer patients. activate p53 at times of crisis (Michael and Oren, 2003).
Now a recent study from the Levine laboratory has
While we are all acutely aware of the alarmingly high demonstrated an extremely important mechanism of
incidence of cancer in people, these numbers obscure regulatingMdm2 expression that contributes to not only
the fact that at a cellular level, full malignant transforma- the development of cancer through the acquisition of
tion is an extremely rare occurrence. We are, in fact, somatic alterations, but also to our overall susceptibility
efficiently protected from tumorigenesis by a complex to cancer (Bond et al., 2004). A single nucleotide poly-
array of checkpoints and failsafe mechanisms. Indeed, morphism (SNP) comprising a T-to-G change within the
malignant development seems possible only following Mdm2 promoter has been shown to result in an in-
some kind of a breakdown in these systems. As we creased affinity for the transcription factor Sp1, and,
begin to piece together the pathways and networks thus, higher expression of Mdm2 RNA and protein. In
though which tumor suppression is mediated, a number a sample of healthy volunteers, the frequency of this
of key control points that are commonly perturbed dur- difference was found to be high—around 50% of the
ing malignant progression are being revealed. Under- sample population being homozygous for T/T, 40% het-
standing where and how these catastrophic failures in erozygous for T/G, and 10% homozygous for G/G. Most
our defense against cancer occur is bringing us closer strikingly, people either heterozygous for T/G or G/G
homozygotes showed a dramatic increase in both can-to the development of therapeutics aimed at repairing
cer incidence and time of cancer onset, an effect thatthese critical lesions, and thereby reinstating activities
was seen in both Li Fraumeni syndrome patients, wherethat may prevent, or even cure, the disease.
the p53 pathway is already weakened by mutation inOne of themost important components of the systems
one p53 allele, and in sporadic tumor incidence in thethat keep us relatively free of cancer is the p53 protein,
general population. These observations suggest verywith evidence for a malfunction in the p53 pathway in
strongly that elevated levels of Mdm2 expression canmost cancers (Vogelstein et al., 2000). The most com-
have a significant impact in dampening the efficiencymon—and probably most efficient—mechanism for loss
of tumor suppression by p53, a concept supported byof p53 function is through mutation within the p53 gene
studies in mice showing profound effects of very subtleitself, leading to the expression of a mutant protein.
alterations in the levels of Mdm2 expression (MendrysaHowever, about half of all cancers retain the ability to
et al., 2003). Clearly, much larger cohorts need to beexpress a normal p53 protein, andmany of these tumors
examined to ascertain the generality of these observa-show defects in the ability to respond to p53. There
tions, but if confirmed, the high frequency of this Mdm2is now much excitement surrounding the therapeutic
SNPwill have a profound impact on our ability to predictpossibilities of reactivating p53 in cancers, but it seems
cancer rates in large numbers of people and may evenclear that to succeed in such approaches, we will need
influence screening, follow up, and treatment options.to understand how p53 function was lost in the first
The results of Bond et al.’s work are entirely in lineplace. A number of recent papers have shed light on
with many other studies that have identified alterationsvarious aspects of this question and have served to both
in the pathways that control Mdm2 activity as linkedilluminate and bring further complexity to these issues.
with cancer development. The idea that p53 activity canThe potent growth inhibitory activities of p53 that play
be perturbed through more than one mechanism leadssuch a useful role in preventing the outgrowth of cells
to the interesting question of whether there is redun-with malignant tendencies are also extremely detrimen-
dancy in these alterations; in other words, can one de-tal to normal growth and development. p53 activity is
fect in the p53 pathway functionally substitute for an-
other? Certainly the observation that defects upstream
of p53 often occur in those cancers that retain wild-*Correspondence: clp3@columbia.edu
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type p53 has supported this notion of redundancy. So, p53 over the wild-type form and the ability of mutant
forms of p53 to regulate gene expression, cell growth,superficially, we might predict that overexpression of
Mdm2 will be functionally equivalent to mutation in p53. and cell death independently of wild-type p53 (Cadwell
and Zambetti, 2001; Sigal andRotter, 2000). Such exper-However, a growing body of evidence for p53-indepen-
dent activities of Mdm2 suggests that overexpression iments have included cell-based assays involving either
transient or stable expression of mutant p53 or use ofofMdm2will have effects beyond disabling p53 (Ganguli
and Wasylyk, 2003). Several other potential targets of a mouse xenograph transplantation tumor model com-
paring tumors caused by p53 null mouse cells to theMdm2 ubiquitination have been described, each of
which is independent of p53, and while not proven, it same cells expressing human hot-spot mutant forms of
p53. Such experiments have supported the likelihoodseems plausible that an excess of Mdm2 activity will
have effects on cell growth and survival that would not that both mechanisms are in play. Nevertheless, since
these studies have involved at least one artificial compo-be mimicked in cells where p53 function has been
lost directly. nent (for example, use of ectopically expressed protein),
the concept that mutant forms of p53 are pro-oncogenicInterestingly, the question of how interchangeable dif-
ferent types of alterations in the p53 pathway really are has been questioned. Lacking results of experiments
that examine mutant forms of p53 expressed from theirhas also been addressed from a completely different
angle by two further recent papers from the Jacks and endogenous locus, it has been difficult to reach a defini-
tive conclusion as to whether and how mutant forms ofLozano laboratories examining the consequences of
mutant p53 expression in mice (Lang et al., 2004; Olive p53 normally affect the development of cancer.
To address these issues, Olive et al. and Lang et al.et al., 2004). While mice lacking p53 expression have
been analyzed extensively and to great effect, we really generated mice that were either heterozygous at the
p53 locus (mt/) or expressed only mutant p53 (mt/mt).cannot ignore the fact that in human cancers, ablation
of p53 function due to mutation is rarely associated with While Lang et al. generated only one knockin mutant
(R172H), Olive et al. tested two mutant forms of p53the loss of p53 protein expression (or even expression
of an functionless unstable p53 protein fragment). The (R172H and R270H) that each represent examples, re-
spectively, of conformational and contact hot spot mu-mechanism of mutational inactivation of p53, compared
to other tumor suppressor proteins, remains remark- tants. Their results provide support for both dominant-
negative and gain-of function properties of mutantable. In the majority of cases (i.e., in about half of all
human cancers), tumor-associated p53 mutations are p53 proteins.
There are two interrelated reasons why generation ofalmost always a single aminoacid substitutionwithin the
central DNA binding core domain, and they frequently heterozygotes (mt/) expressing both the mutant and
the wild-type p53 allele is important. First, as mentionedresult in the expression of p53 protein at higher levels
than wild-type p53. While nearly every residue in the above, it is of interest to evaluate the extent to which
mutant forms of p53 can serve to downregulate the wild-sequence-specific core DNA binding domain has been
found mutated in human tumors, there are among these type form of the protein by forming inactive hetero-
tetramers. Second, cancer-prone Li-Fraumeni familyapproximately six hot spots for mutation that together
comprise nearly 40% of all these mutations. Such muta- members possess a germline mutant form of p53 ,and
generation of suchmice could genotypically and pheno-tions either affect direct DNA contacts of the core or
have a more general effect on the conformation of this typically mimic such patients’ disease characteristics.
Indeed, when Olive et al., compared their mt/ mice todomain. Why such strong selection for the expression
of mutant p53 exists in cancers has been the topic of p53/ mice significant differences in tumor spectra
were observed. R270H/ mice had numerous carcino-much speculation. Is the acquisition of a mutant p53 (as
seen in human cancer) equivalent to the loss of p53 mas (a form of cancer that is very rare in / mice)
that were more invasive and metastatic, as well as analtogether (as in the knockout mice)? In other words,
are themissensemutant forms of p53 essentially neutral increased frequency of B cell lymphomas. On the other
hand, R172H/ mice had increased frequency of meta-versions that lack both tumor-suppressing and -promot-
ing function, or do they contribute to the process of static osteosarcomas. In their study about half of the
tumors had lost the wild-type allele. These data suggestcancer progression? There are numerous lines of evi-
dence derived from basic and clinical studies that have that while the dominant negative effect of mutants is
possible, there is likely to be some additional compo-favored the latter possibility although until recently none
have provided either definitive physiological evidence nent(s) provided by mutant p53 in this model. This is
consistent with a result from Lang et al. based on thefor this or extensive mechanistic insight. One possible
explanation is that these mutant p53 proteins oligo- fact that loss of p53 rescues the early embryonic lethal
phenotype of knocking out Mdm2. If mutant p53 servesmerize with wild-type p53 through the C-terminal tetra-
merization domain and so inactivate any wild-type p53 to fully and solely block wild-type p53 function, then
mt/ mice should also rescue the Mdm2/ lethality, acoexpressed in the cells though a dominant-negative
mechanism. This may certainly contribute to the prefer- result that was not observed.
To determine whether the mutant p53 present in aential selection of this type of mutations, but is unlikely
to be the whole story. For one thing, advanced tumors cell that lacks wild-type p53 has any function, the Jacks
group generated mice expressing only each of the mu-rarely possess both wild-type and mutant forms of p53;
loss of heterozygosity at the p53 locus is a very frequent tant p53 hot spot alleles described above. Indeed, they
found mutant p53-bearing mice displayed a marked dif-event, with tumors retaining only the mutant form of
the protein. ference in tumor spectra, with carcinomas, hemangisar-
comas, and T cell lymphomas occurring with signifi-In fact, there is a rather extensive literature document-
ing both dominant-negative effects of mutant forms of cantly higher frequencies than seen in / mice. When
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amination of mutant p53 in the engineered mice pro-
duced by both groups showed that high levels of mutant
p53 were found in the majority (but not all) of the tumors
that were examined. In contrast, normal cells from these
mice did not express high levels of mutant p53. This
suggests that the environment of a tumor cell has one
or more secondary events that are required to stabilize
p53 other than the simple lack of inducedMdm2. Further
experiments performed by both groups using cells cul-
tured from themice showed that the presence of mutant
p53 has a promoting effect on cell growth and division
in the absence of any wild-type p53.
Thus, the two groups have come to essentially the
same conclusion (although with some differences in
their data sets) that the presence of a mutant p53 influ-
ences the process of tumorigenesis in a manner that
can be distinct from simply deleting wild-type p53. How
might such an oncogenic gain of function be broughtFigure 1. More Than One Way to Block p53
about? Two (or more) discrete mechanisms have beenWhile loss of p53 activity appears to be essential for malignant
proposed. In one case, mutant p53 may have directprogression, there are several routes through which this can be
effects on gene expression that differ from that of wild-achieved. Each of these different mechanisms blocks p53 activity,
but their downstream effectsmay be profoundly different. Examples type p53. Indeed, transient reporter assays have identi-
shown here are the expression of mutant forms of p53 or expression fied a number of possible promoters that are differen-
of excess Mdm2. Both may inhibit the regulation of target genes tially affected by wild-type and mutant forms of p53,
involved in tumor suppression by either p53 or p53 homologs p63 and, more recently, mutant but not wild-type p53 has
and p73. However, mutant p53 and Mdm2 each have additional
been found associated with chromatin in the promoterunique targets, and perturbations in these may result in important
of the CD95(Fac/APO-1) gene, leading to its repressiondifferences in the phenotype of the resulting tumor.
(Zalcenstein et al., 2003). An alternatemechanismposits
that mutant p53 may be able, in some cases, to prevent
Lang et al. generated heterozygous (mt/), hemizygous other p53 family members from functioning properly.
(mt/), and homozygous (mt/mt) R172Hmice, their data A number of studies have shown that ectopically or
also led to the conclusion that mutant p53 has effects endogenously expressed mutant p53 can interact with
on cells and mice that differ from the situation where and downregulate the function of wild-type p63 or p73
p53 is absent. But there were differences in their results: (p63/p73) proteins (Moll et al., 2001). It is noteworthy
Lang et al. found that the types of tumors present were that their interaction is not through the tetramerization
mostly lymphomas and sarcomas, with a low frequency region but is mediated through their core domains. Con-
of carcinomas, although in their study, 53/ and mt/ sistent with the idea of mutant p53 affecting p63/p73,
mt mice had a majority of lymphomas, while p53/ both Olive et al. and Lang et al. showed that endoge-
and /mt mice had a majority of sarcomas. In contrast nously expressedmutant p53 can be found in an immun-
to Olive et al., when the Lozano group compared mt/mt precipitable complex with p63 and p73. Lang et al. went
and / mice, there was no difference in the kinds of further toprovide supporting evidence for themodel that
tumors noted. However, strikingly, the tumors in the 172/ mutant p53s gain of function is at least partly through its
mice metastasized, while those in / mice did not. A ability to block the activity of p63 and p73 (p63/p73).
likely explanation for the differences seen between the They exploited a previous approach by Irwin et al., who
two studies can be related to strain differences: themice downregulated mutant p53 in human cells and thereby
from Jacks were enriched for the genotype of 129S/ increased the activity of p73 (Irwin et al., 2003). Similarly,
SvJae mice, while the Lozano mice were enriched for Lang et al. showed that when p53 siRNAwas introduced
the C57BL/6 background. Regardless of these differ- into a tumor cell line derived from their mt/ mice (that
ences, the above data together support the likelihood had lost the wild-type p53 allele), ectopically expressed
that, in their natural context, mutant p53 proteins can p63 and p73 transactivation of a p21 promoter reporter
affect tumor spectra and properties. Note, however, that construct was increased. Moreover, the same siRNA led
while there were either different or more metastatic tu- to increased expression of endogenous p21 in mouse
mors, mutant p53-expressing mice did not die more cells thatwas presumably the result of increased activity
quickly thanp53nullmice,with both sets averaging about by endogenous p63/p73. Reciprocally, they also found
4.5 months. that siRNA knock-down of p63 and p73 had selective
Additional interesting observations were made. For impact on cells depending upon whether they express
example, it is well described that tumor-derived mis- mutant p53: Ras-induced foci were increased in mt/mt
sense mutant forms of p53 are frequently expressed at cells compared with / cells, and siRNA reduction of
much higher levels than is wild-type p53 in human tu- p63/p73 increased foci in the / cells but not in the
mors. In fact, simply being able to detect p53 by immu- mt/mt cells, suggesting that the p53 homologs were
nostaining is often taken by pathologists as evidence already compromised in the mutant p53 expressing
that a tumor expresses mutant p53. The most likely cells.
explanation for this is that transcriptionally inert mutant All told, it is clear that the p53 pathway can be dis-
forms of p53 cannot induce the synthesis of Mdm2 that rupted through many mechanisms. Although there may
be some redundancy between these, different points ofnormally keeps wild-type p53 levels extremely low. Ex-
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perturbation can result in substantially different results plore. A compound (Nutlin) that disrupts the interaction
(see Figure 1). While these new studies begin to shed between p53 and Mdm2 would be particularly relevant
some light on these complexities, several newquestions topatients that overexpressMdm2 (Vassilev et al., 2004).
also arise from these papers. Alternately (or additively), compounds that can restore
First, despite the striking data with the Mdm2 309 wild-type activity to mutant p53, such as PRIMA (Bykov
polymorphism, it is likely that other SNPs exist that also et al., 2002), or that can disrupt the interaction between
modify the p53 response. How important are they in mutant and p63/p73 would be a very promising start for
determining prognosis and survival? Moreover, are novel therapeutic intervention. The findings from the
there other polymorphisms that modify the response of Levine, Lozano, and Jacks laboratories underscore the
cells to either the SNP309 or other SNPs? It is interesting importance of knowing not only whether, but also how,
to consider the possibility that variations in SNPs might p53 has been disturbed in a cancer. These studies will
explain the differences in tumor development in different certainly provide impetus for further basic and transla-
mouse strains expressing mutant p53. The extremely tional approaches to the ever-increasing complexity of
high frequency of the SNP309 polymorphism, at least the field of p53.
in the populations examined by the Levine group, is also
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Clearly there is still interesting work to be done to
clarify how excess Mdm2 or mutant forms of p53 pro-
mote growth and tumor formation. Moreover, these re-
sults should provide further therapeutic avenues to ex-
